Table 1 Demographic and clinical characteristics of MS patients and controls
HC (n = 30) | RRMS (n = 55) | PMS (n = 18) | p value, HC vs MS | p value, RRMS vs PMS | p value, RRMS vs HC | ||
|---|---|---|---|---|---|---|---|
Age, years (mean ± SD) | 41.1 ± 11.4 | 44.7 ± 12.1 | 60.1 ± 8.0 | < 0.01 | < 0.01 | 0.190 | |
Female sex, n (%) | 18 (60.0%) | 31 (56.40%) | 11 (61.10%) | 0.498 | 0.914 | 0.173 | |
HCMV(+) serology, n (%) | 23 (76.7%) | 35 (63.6%) | 11 (61.1%) | 0.133 | 0.400 | 0.093 | |
EBV(+) serology, n (%) | 24 (85.7%) | 54 (98.2%) | 17 (94.4%) | < 0.05 | 0.075 | < 0.05 | |
MS duration (years) | – | 10.9 (5.5–16.0) | 22.6 (13.9–33.3) | – | < 0.01 | – | |
EDSS | – | 2.0 (1.0–3.0) | 6.0 (4.4–7.0) | – | < 0.01 | – | |
MSSS | – | 2.08 (1.01–4.17) | 6.74 (3.74–7.46) | – | < 0.01 | – | |
2y-RR | – | 0.0 (0.0–1.0) | 0.0 (0.0–0.0) | – | < 0.01 | – | |
ARR | – | 0.31 (0.17–0.57) | 0.0 (0–0.13) | – | < 0.01 | – | |
DMT | None | – | 27 | 18 | < 0.01 | – | |
IFNβ | – | 23 | 0 | ||||
GA | – | 5 | 0 | ||||